Navigation Links
New Drug Application for Ibrutinib Submitted to the U.S. FDA
Date:7/10/2013

SUNNYVALE, Calif., July 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The submission was based on data from Phase II studies in patients with relapsed/refractory MCL and in patients with relapsed/refractory CLL/SLL. With this submission, Pharmacyclics is also requesting Priority Review. Pharmacyclics is jointly developing ibrutinib with Janssen.

The NDA submission follows the receipt of a Breakthrough Therapy Designation from the FDA in February 2013 for ibrutinib as a monotherapy for the treatment of patients with relapsed/refractory MCL, and receipt of a second Breakthrough Therapy Designation for the treatment of patients with CLL/SLL with deletion of the short arm of chromosome 17 (del 17p). Further information on the implications of this filing for potential commercialization will be provided subsequent to the FDA rendering a decision on the filing.

"We are very excited having achieved this major milestone. This first NDA for ibrutinib was made possible in record time because of the continuous support and consultations we received from the FDA," said Dr. Urte Gayko, Senior Vice President of Global Regulatory Affairs, Pharmacyclics. "We look forward to continuing to work with the FDA as they review the application for ibrutinib through the new Breakthrough Therapy Designation process."

"These past months have been enormously active and productive for Pharmacyclics and our ibrutinib partner, Janssen. We received our first of three Breakthroug
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
2. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
3. Bio-AMD, Inc.; Patent Application for Cartridge Test Cap
4. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
5. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
9. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
10. Clinical Safety Data for ChromaDex®s Patented pTeroPure® (pterostilbene) Released at 6th World Congress on Polyphenols Applications in Paris
11. UltraTape announces Cleanroom Labels for Cryogenic Laboratory applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology company ... announced today that Daniel P. Gold , Ph.D., President ... PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 3:40 ... New York . A live webcast of ... replay will be available approximately one hour after the presentation. ...
(Date:8/4/2015)...  Intec Pharma Ltd. (the "Company") (NASDAQ: NTEC ... drugs based on its proprietary Accordion Pill platform technology, ... in the United States of ... the public of $6.00 per ordinary share, before underwriting ... being offered by the Company.  In addition, the Company ...
(Date:8/4/2015)... 4, 2015 Concord Medical Services Holdings Limited ("Concord ... management solution provider and operator of the largest network of ... , today announced it will release its financial results for ... August 17, 2015. Management will hold a conference ... a.m. EDT on August 18, 2015 (8:00 p.m. in ...
Breaking Medicine Technology:MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2
... CITY, June 23, 2011 PD-Rx Pharmaceuticals, Inc., ... the purchase of the Washington EMR, an electronic ... Washington EMR is the premier quality, low-cost ... The intuitive interface allows the physician and assistants ...
... SAN DIEGO, June 23, 2011 BioSurplus today announced ... of instruments worth over $10 million will be auctioned ... The first auction will have choice laboratory equipment ... HPLCs and Mass Specs, Molecular Devices Spectramax M5 plate ...
Cached Medicine Technology:PD-Rx Pharmaceuticals Acquires Wilson Medical's EMR 2BioSurplus Selected to Auction $10 Million in Lab Equipment 2
(Date:8/4/2015)... ... August 04, 2015 , ... Ryadon Inc. will now provide ... hardware can be difficult and troublesome for companies. Without dependable hardware, many ... a new facility, it is imperative to include only the finest, most dependable ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... States, Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors effective August ... save lives," Dr. Carmona said. "I strongly believe in the mission of the ...
(Date:8/4/2015)... ... 04, 2015 , ... Recent studies in the ... in binge drinking among certain populations and specific locations. Researchers, who ... examine trends and evidence to help facilitate health care treatment to meet current ...
(Date:8/4/2015)... ... August 04, 2015 , ... 24/7 Care At ... Angeles, Riverside, and San Bernardino, today announced that the U.S. Department of Veteran’s Affairs ... 24/7 Care At Home’s agency is well on the path to meeting the aspirational ...
(Date:8/4/2015)... Francisco, Calif. (PRWEB) , ... August 04, 2015 ... ... to corporations, law firms and government entities, today announced that John Munro, a ... team as Vice President of Managed Services Operations. , “I am thrilled to ...
Breaking Medicine News(10 mins):Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 3Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 4Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3
... in low sunlight areas are more likely to experience ... same environment. Researchers believe that these findings should change ... study shows that across the board vitamin D recommendations ... M.D., M.B.A., clinical instructor in the department of urology ...
... well-known risk factor for heart disease. Researchers at the ... participated in an international study of 200,000 Europeans which ... pressure. The discovery, presented in Nature, is an important ... people worldwide suffer from high blood pressure and are ...
... in areas with low sunlight are up to 3 ... men and should take high levels of Vitamin D supplements, ... of Medicine. "This study shows that the current ... Vitamin D don,t work," said Adam Murphy, M.D., a clinical ...
... Tenn. September 19, 2011) The largest study ever of ... tumors carried extra copies of specific genes linked to cancer ... Hospital investigators. The findings identify possible new targets ... diffuse intrinsic pontine glioma (DIPG). Current survival rates for children ...
... , MONDAY, Sept. 19 (HealthDay News) -- Obese 8- ... than their normal-weight peers, a new study finds. In ... of height and weight, at ages 4 and 5 and ... out questionnaires that assessed children,s mental health and health-related quality ...
... HealthDay Reporter , MONDAY, Sept. 19 (HealthDay News) -- ... treating varicose veins, it appears that recurrence of one ... laser treatment, German researchers report. Varicose veins are ... legs. As many as 35 percent of adults suffer ...
Cached Medicine News:Health News:African-American men living in poor sunlight areas at risk for vitamin D deficiency 2Health News:Genetic factors behind high blood pressure 2Health News:One size doesn't fit all for vitamin D and men 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 3Health News:Obese Kids May Face Social, Emotional Woes 2Health News:Obese Kids May Face Social, Emotional Woes 3Health News:Two Varicose Veins Treatments Equally Effective 2Health News:Two Varicose Veins Treatments Equally Effective 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a scientifically advanced nutritional formulation that ... full body health. MacularProtect Complete-S, based ... other advanced research, delivers a diverse ... mg of FloraGLO® lutein and other ...
... PreserVision® Soft Gel Lutein patented formula is ... Lomb PreserVision® AREDS formula, with the beta-carotene ... Lutein is a carotenoid found in dark ... is highly concentrated in the macula, the ...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re...
Medicine Products: